L–Carnitine in Metabolic Dysfunction-Associated Steatotic Liver Disease: Mechanisms and Therapeutic Potential

Why It Matters

MASLD drives major morbidity and mortality worldwide; an inexpensive supplement that targets its core metabolic pathways could shift treatment paradigms. Demonstrated efficacy in both animal studies and human trials positions L‑carnitine as a promising therapeutic candidate.

Key Takeaways

• MASLD affects ~30% of world population.
• L‑carnitine enhances mitochondrial β‑oxidation via CPT1/2.
• Supplementation improves insulin sensitivity and lowers liver enzymes.
• Clinical trials show reduced hepatic fat with 2‑4 g/day.
• Modulates AMPK‑SIRT1‑PPAR‑PGC1α signaling to curb fibrosis.

Pulse Analysis

MASLD, formerly known as NAFLD, has emerged as a leading cause of chronic liver disease, affecting roughly 30 percent of adults worldwide. Its rise mirrors global increases in obesity, type 2 diabetes, and sedentary lifestyles, creating a pressing need for scalable interventions beyond diet and exercise. While several pharmacologic agents are in development, many remain costly or limited to advanced disease stages, leaving a therapeutic gap for early‑stage patients. L‑carnitine, an essential nutrient involved in fatty‑acid transport, offers a compelling alternative because of its established safety profile and inexpensive manufacturing.

Mechanistically, L‑carnitine acts as a shuttle that moves long‑chain fatty acids into mitochondria for β‑oxidation, a process governed by CPT1 and CPT2 enzymes. Supplementation restores intracellular carnitine pools that are often depleted in MASLD, thereby re‑activating the AMPK‑SIRT1‑PPAR‑PGC1α axis. This signaling cascade not only accelerates fatty‑acid catabolism but also suppresses lipogenic transcription factors such as SREBP‑1c, reduces oxidative stress, and curtails inflammatory cytokine production. Animal studies across rodents and medaka fish consistently demonstrate lower hepatic triglycerides, improved insulin signaling, and attenuated fibrosis when L‑carnitine is added to high‑fat diets, supporting a biologically plausible pathway for disease modification.

Clinically, randomized trials have begun to translate these findings, showing that daily doses of 2–4 g of L‑carnitine can decrease liver fat fraction measured by MRI‑PDFF and improve serum lipid panels in patients with early‑stage MASLD. The modest yet statistically significant reductions in ALT, AST, and fasting glucose suggest broader metabolic benefits. As a supplement that can be combined with lifestyle counseling or emerging agents like GLP‑1 receptor agonists, L‑carnitine may help sustain weight‑loss‑induced improvements and prevent relapse. Ongoing large‑scale trials will clarify optimal dosing, patient selection, and long‑term safety, but current evidence positions L‑carnitine as a viable, cost‑effective tool in the MASLD therapeutic arsenal.